FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2143158562> ?p ?o ?g. }

• W2143158562 endingPage "F23" @default.
• W2143158562 startingPage "F12" @default.
• W2143158562 abstract "The worldwide prevalence of infection with human papillomavirus (HPV) in women without cervical abnormalities is 11-12% with higher rates in sub-Saharan Africa (24%), Eastern Europe (21%) and Latin America (16%). The two most prevalent types are HPV16 (3.2%) and HPV18 (1.4%). Prevalence increases in women with cervical pathology in proportion to the severity of the lesion reaching around 90% in women with grade 3 cervical intraepithelial neoplasia and invasive cancer. HPV infection has been identified as a definite human carcinogen for six types of cancer: cervix, penis, vulva, vagina, anus and oropharynx (including the base of the tongue and tonsils). Estimates of the incidence of these cancers for 2008 due to HPV infection have been calculated globally. Of the estimated 12.7 million cancers occurring in 2008, 610,000 (Population Attributable Fraction [PAF]=4.8%) could be attributed to HPV infection. The PAF varies substantially by geographic region and level of development, increasing to 6.9% in less developed regions of the world, 14.2% in sub-Saharan Africa and 15.5% in India, compared with 2.1% in more developed regions, 1.6% in Northern America and 1.2% in Australia/New Zealand. Cervical cancer, for which the PAF is estimated to be 100%, accounted for 530,000 (86.9%) of the HPV attributable cases with the other five cancer types accounting for the residual 80,000 cancers. Cervical cancer is the third most common female malignancy and shows a strong association with level of development, rates being at least four-fold higher in countries defined within the low ranking of the Human Development Index (HDI) compared with those in the very high category. Similar disparities are evident for 5-year survival-less than 20% in low HDI countries and more than 65% in very high countries. There are five-fold or greater differences in incidence between world regions. In those countries for which reliable temporal data are available, incidence rates appear to be consistently declining by approximately 2% per annum. There is, however, a lack of information from low HDI countries where screening is less likely to have been successfully implemented. Estimates of the projected incidence of cervical cancer in 2030, based solely on demographic factors, indicate a 2% increase in the global burden of cervical cancer, i.e., in balance with the current rate of decline. Due to the relative small numbers involved, it is difficult to discern temporal trends for the other cancers associated with HPV infection. Genital warts represent a sexually transmitted benign condition caused by HPV infection, especially HPV6 and HPV11. Reliable surveillance figures are difficult to obtain but data from developed countries indicate an annual incidence of 0.1 to 0.2% with a peak occurring at teenage and young adult ages. This article forms part of a special supplement entitled Comprehensive Control of HPV Infections and Related Diseases Vaccine Volume 30, Supplement 5, 2012." @default.
• W2143158562 created "2016-06-24" @default.
• W2143158562 creator A5000887223 @default.
• W2143158562 creator A5003542814 @default.
• W2143158562 creator A5003920321 @default.
• W2143158562 creator A5037728205 @default.
• W2143158562 creator A5051830072 @default.
• W2143158562 creator A5052073140 @default.
• W2143158562 creator A5057880586 @default.
• W2143158562 creator A5064215217 @default.
• W2143158562 creator A5071864458 @default.
• W2143158562 creator A5081436119 @default.
• W2143158562 creator A5089989499 @default.
• W2143158562 date "2012-11-01" @default.
• W2143158562 modified "2023-10-16" @default.
• W2143158562 title "Global Burden of Human Papillomavirus and Related Diseases" @default.
• W2143158562 cites W1981989535 @default.
• W2143158562 cites W1984585202 @default.
• W2143158562 cites W1986771898 @default.
• W2143158562 cites W2006200510 @default.
• W2143158562 cites W2006274713 @default.
• W2143158562 cites W2010948558 @default.
• W2143158562 cites W2014166788 @default.
• W2143158562 cites W2020386919 @default.
• W2143158562 cites W2022090849 @default.
• W2143158562 cites W2023668318 @default.
• W2143158562 cites W2026996973 @default.
• W2143158562 cites W2034336513 @default.
• W2143158562 cites W2039745983 @default.
• W2143158562 cites W2041176483 @default.
• W2143158562 cites W2052263121 @default.
• W2143158562 cites W2053746256 @default.
• W2143158562 cites W2058375382 @default.
• W2143158562 cites W2059354102 @default.
• W2143158562 cites W2064729122 @default.
• W2143158562 cites W2079614322 @default.
• W2143158562 cites W2086141003 @default.
• W2143158562 cites W2089569798 @default.
• W2143158562 cites W2093106099 @default.
• W2143158562 cites W2095248428 @default.
• W2143158562 cites W2103680668 @default.
• W2143158562 cites W2106115615 @default.
• W2143158562 cites W2108334238 @default.
• W2143158562 cites W2108397955 @default.
• W2143158562 cites W2118632290 @default.
• W2143158562 cites W2121401564 @default.
• W2143158562 cites W2127728552 @default.
• W2143158562 cites W2131103881 @default.
• W2143158562 cites W2132655544 @default.
• W2143158562 cites W2134728470 @default.
• W2143158562 cites W2135045906 @default.
• W2143158562 cites W2138584423 @default.
• W2143158562 cites W2150550346 @default.
• W2143158562 cites W2155942218 @default.
• W2143158562 cites W2158893040 @default.
• W2143158562 cites W2164710273 @default.
• W2143158562 cites W2165339119 @default.
• W2143158562 cites W2168814757 @default.
• W2143158562 cites W2170147411 @default.
• W2143158562 cites W4250577753 @default.
• W2143158562 doi "https://doi.org/10.1016/j.vaccine.2012.07.055" @default.
• W2143158562 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23199955" @default.
• W2143158562 hasPublicationYear "2012" @default.
• W2143158562 type Work @default.
• W2143158562 sameAs 2143158562 @default.
• W2143158562 citedByCount "1224" @default.
• W2143158562 countsByYear W21431585622012 @default.
• W2143158562 countsByYear W21431585622013 @default.
• W2143158562 countsByYear W21431585622014 @default.
• W2143158562 countsByYear W21431585622015 @default.
• W2143158562 countsByYear W21431585622016 @default.
• W2143158562 countsByYear W21431585622017 @default.
• W2143158562 countsByYear W21431585622018 @default.
• W2143158562 countsByYear W21431585622019 @default.
• W2143158562 countsByYear W21431585622020 @default.
• W2143158562 countsByYear W21431585622021 @default.
• W2143158562 countsByYear W21431585622022 @default.
• W2143158562 countsByYear W21431585622023 @default.
• W2143158562 crossrefType "journal-article" @default.
• W2143158562 hasAuthorship W2143158562A5000887223 @default.
• W2143158562 hasAuthorship W2143158562A5003542814 @default.
• W2143158562 hasAuthorship W2143158562A5003920321 @default.
• W2143158562 hasAuthorship W2143158562A5037728205 @default.
• W2143158562 hasAuthorship W2143158562A5051830072 @default.
• W2143158562 hasAuthorship W2143158562A5052073140 @default.
• W2143158562 hasAuthorship W2143158562A5057880586 @default.
• W2143158562 hasAuthorship W2143158562A5064215217 @default.
• W2143158562 hasAuthorship W2143158562A5071864458 @default.
• W2143158562 hasAuthorship W2143158562A5081436119 @default.
• W2143158562 hasAuthorship W2143158562A5089989499 @default.
• W2143158562 hasBestOaLocation W21431585622 @default.
• W2143158562 hasConcept C107130276 @default.
• W2143158562 hasConcept C120665830 @default.
• W2143158562 hasConcept C121332964 @default.
• W2143158562 hasConcept C121608353 @default.
• W2143158562 hasConcept C126322002 @default.
• W2143158562 hasConcept C16005928 @default.
• W2143158562 hasConcept C2776316342 @default.

• next